S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
S&P 500   3,145.91 (+0.91%)
DOW   28,015.06 (+1.22%)
QQQ   205.00 (+1.07%)
AAPL   270.71 (+1.93%)
FB   201.05 (+0.85%)
MSFT   151.75 (+1.21%)
GOOGL   1,339.39 (+0.94%)
AMZN   1,751.60 (+0.64%)
CGC   18.65 (+0.27%)
NVDA   212.17 (+1.64%)
MU   47.93 (+2.81%)
BABA   201.89 (+0.95%)
GE   11.10 (+2.87%)
TSLA   335.89 (+1.67%)
T   38.20 (+0.03%)
AMD   39.63 (+0.03%)
ACB   2.43 (-0.41%)
F   9.02 (+1.01%)
PRI   135.68 (+1.03%)
NFLX   307.35 (+1.48%)
BAC   33.67 (+1.75%)
GILD   67.08 (+1.74%)
DIS   147.66 (+0.15%)
Log in

NASDAQ:EXAS - EXACT Sciences Stock Price, Forecast & News

$86.24
+2.63 (+3.15 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$84.01
Now: $86.24
$86.80
50-Day Range
$77.66
MA: $85.41
$98.57
52-Week Range
$53.06
Now: $86.24
$123.99
Volume2.04 million shs
Average Volume1.85 million shs
Market Capitalization$11.20 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.32
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXAS
CUSIP30063P10
Phone608-535-8815

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$454.46 million
Book Value$5.54 per share

Profitability

Net Income$-175,150,000.00

Miscellaneous

Employees1,977
Market Cap$11.20 billion
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.


EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions

What is EXACT Sciences' stock symbol?

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

How were EXACT Sciences' earnings last quarter?

EXACT Sciences Co. (NASDAQ:EXAS) posted its earnings results on Tuesday, October, 29th. The medical research company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.10. The medical research company earned $218.81 million during the quarter, compared to analysts' expectations of $216.14 million. EXACT Sciences had a negative net margin of 29.83% and a negative return on equity of 29.06%. EXACT Sciences's quarterly revenue was up 85.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.37) EPS. View EXACT Sciences' Earnings History.

When is EXACT Sciences' next earnings date?

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for EXACT Sciences.

What price target have analysts set for EXAS?

14 Wall Street analysts have issued 1-year price targets for EXACT Sciences' shares. Their forecasts range from $102.00 to $143.00. On average, they expect EXACT Sciences' stock price to reach $123.62 in the next twelve months. This suggests a possible upside of 43.3% from the stock's current price. View Analyst Price Targets for EXACT Sciences.

What is the consensus analysts' recommendation for EXACT Sciences?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for EXACT Sciences.

What are Wall Street analysts saying about EXACT Sciences stock?

Here are some recent quotes from research analysts about EXACT Sciences stock:
  • 1. According to Zacks Investment Research, "EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. " (10/17/2019)
  • 2. Canaccord Genuity analysts commented, "We are buyers of EXAS following the unusual 10% weakness in shares today, which we believe were part of the overall selloff today in diagnostics (and software stocks), where much of the alpha in the overall stock market has come from; and what we believe is likely certain funds pressuring EXAS following a cost effectiveness study published last week, but got a lot more attention today on the Street. We believe this is a buy-on- weakness opportunity on shares of EXAS given a handful of deep flaws used in the study." (9/10/2019)

Has EXACT Sciences been receiving favorable news coverage?

News stories about EXAS stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. EXACT Sciences earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave news stories about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for EXACT Sciences.

Who are some of EXACT Sciences' key competitors?

What other stocks do shareholders of EXACT Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other EXACT Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Micron Technology (MU), Aduro BioTech (ADRO), Alibaba Group (BABA), Paypal (PYPL), salesforce.com (CRM), Puma Biotechnology (PBYI), Advanced Micro Devices (AMD) and BioMarin Pharmaceutical (BMRN).

Who are EXACT Sciences' key executives?

EXACT Sciences' management team includes the folowing people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 53)
  • Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 41)
  • Mr. Graham P. Lidgard, Chief Science Officer (Age 70)
  • Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Mark Stenhouse, Pres of Cologuard (Age 52)

Who are EXACT Sciences' major shareholders?

EXACT Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Eagle Asset Management Inc. (0.84%), First Trust Advisors LP (0.68%), Sumitomo Mitsui Trust Holdings Inc. (0.37%), Columbus Circle Investors (0.35%), KAMES CAPITAL plc (0.31%) and Russell Investments Group Ltd. (0.22%). Company insiders that own EXACT Sciences stock include D Scott Coward, G Bradley Cole, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Mark Stenhouse, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

Which institutional investors are selling EXACT Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, First Trust Advisors LP, Voya Investment Management LLC, Pictet Asset Management Ltd., Artemis Investment Management LLP, Kornitzer Capital Management Inc. KS, KAMES CAPITAL plc and Russell Investments Group Ltd.. Company insiders that have sold EXACT Sciences company stock in the last year include D Scott Coward, G Bradley Cole, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse and Scott C Johnson. View Insider Buying and Selling for EXACT Sciences.

Which institutional investors are buying EXACT Sciences stock?

EXAS stock was acquired by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Columbus Circle Investors, California Public Employees Retirement System, Handelsbanken Fonder AB, Squarepoint Ops LLC, Zweig DiMenna Associates LLC, Gateway Investment Advisers LLC and Creative Planning. View Insider Buying and Selling for EXACT Sciences.

How do I buy shares of EXACT Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is EXACT Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $86.24.

How big of a company is EXACT Sciences?

EXACT Sciences has a market capitalization of $11.20 billion and generates $454.46 million in revenue each year. The medical research company earns $-175,150,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. EXACT Sciences employs 1,977 workers across the globe.View Additional Information About EXACT Sciences.

What is EXACT Sciences' official website?

The official website for EXACT Sciences is http://www.exactsciences.com/.

How can I contact EXACT Sciences?

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-535-8815.


MarketBeat Community Rating for EXACT Sciences (NASDAQ EXAS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  804 (Vote Outperform)
Underperform Votes:  494 (Vote Underperform)
Total Votes:  1,298
MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe EXAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Featured Article: 12b-1 Fees

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel